Tin Mesoporphyrin IX (chloride): Potent Heme Oxygenase Inhibitor for Metabolic and Antiviral Research

Executive Summary: Tin Mesoporphyrin IX (chloride) is a nanomolar, competitive inhibitor of heme oxygenase (HO) with a Ki of 14 nM, enabling precise modulation of heme catabolism in vitro and in vivo (APExBIO). It is used extensively in metabolic disease, insulin resistance, and viral pathogenesis studies due to its reproducible activity and stability. The compound has been shown to reduce serum bilirubin levels and inhibit hepatic, renal, and splenic HO activity after administration at 1 pmol/kg body weight in animal models. Recent research highlights its relevance in heme oxygenase signaling, including indirect effects on viral replication through HO-1 modulation (Koyaweda et al., 2026). This article provides a structured, evidence-backed overview for research practitioners.

Biological Rationale

Heme oxygenase (HO) is an essential enzyme that degrades heme into biliverdin, carbon monoxide (CO), and ferrous iron (Fe²⁺). There are two primary isoforms: HO-1 (inducible) and HO-2 (constitutive). The HO pathway plays a pivotal role in cellular redox homeostasis, regulation of inflammation, and metabolic signaling (Koyaweda et al., 2026). Aberrant HO activity is implicated in metabolic diseases, insulin resistance, and metaflammation. Inhibition of HO-1, in particular, allows researchers to dissect the contribution of heme catabolism to disease phenotypes and to model the effect of elevated intracellular heme. Tin Mesoporphyrin IX (chloride) is the gold-standard small-molecule tool for these investigations, offering nanomolar potency and competitive inhibition of both HO-1 and HO-2 isoforms (compare—this article extends coverage to include recent antiviral mechanisms).

Mechanism of Action of Tin Mesoporphyrin IX (chloride)

Tin Mesoporphyrin IX (chloride) acts as a competitive inhibitor by binding to the active site of heme oxygenase, displacing heme as a substrate. Its chemical formula is C₃₄H₃₄Cl₂N₄O₄Sn·2H, with a molecular weight of 754.3 g/mol. The compound is highly soluble in dimethyl sulfoxide (DMSO) up to 0.5 mg/mL and in dimethylformamide (DMF) up to 1 mg/mL. The affinity constant (Ki) is 14 nM, demonstrating strong inhibition under standard assay conditions (pH 7.4, 37°C). Upon administration (1 pmol/kg body weight, in vivo), Tin Mesoporphyrin IX (chloride) leads to rapid and sustained inhibition of hepatic, renal, and splenic HO activity. This results in decreased conversion of heme to biliverdin and downstream bilirubin, and increased heme-dependent enzyme saturation (notably hepatic tryptophan pyrrolase). The blockade of heme degradation interrupts downstream HO-1 signaling, impacting redox balance and related metabolic pathways (strategic context—this article updates on viral and metabolic intersections).

Evidence & Benchmarks

• Tin Mesoporphyrin IX (chloride) inhibits HO activity in vitro and in vivo with a Ki of 14 nM (APExBIO product data, product page).
• 1 pmol/kg body weight administration in animal models yields sustained hepatic, renal, and splenic HO inhibition and measurable reduction in serum bilirubin (APExBIO, see specs).
• HO-1 upregulation is linked to antiviral effects in HBV models via reactive oxygen species (ROS) modulation, underscoring the importance of HO pathway manipulation (Koyaweda et al., 2026).
• The compound is a crystalline solid, stable at -20°C, and recommended for short-term solution use to maintain potency (APExBIO technical sheet, C5606 kit).
• No clinical trials involving Tin Mesoporphyrin IX (chloride) have been published as of June 2024 (APExBIO, PubMed search).

Applications, Limits & Misconceptions

Tin Mesoporphyrin IX (chloride) is primarily used in basic and translational research for:

• Heme oxygenase activity assays: Quantifying the functional inhibition of HO-1/HO-2 in cell extracts and tissues.
• Metabolic disease research: Modeling the role of heme catabolism in obesity, diabetes, and insulin resistance (this article details translational perspectives; here we focus on mechanistic and stability data).
• Antiviral research: Investigating the modulation of HO-1 in viral replication, notably in hepatitis B virus (HBV) models, where HO-1 upregulation impairs viral morphogenesis and cccDNA maintenance (Koyaweda et al., 2026).
• Metaflammation studies: Dissecting the cross-talk between HO signaling and inflammatory pathways.

Common Pitfalls or Misconceptions

• Not a clinical therapeutic: No clinical data support its use in humans; it is for research only.
• Reversibility: The inhibition of HO by Tin Mesoporphyrin IX (chloride) is competitive and reversible; it does not result in enzyme destruction.
• Isoform selectivity: It inhibits both HO-1 and HO-2, not selectively HO-1.
• Solution stability: Solutions are stable short-term only; long-term storage reduces potency.
• Not a direct antiviral: Antiviral effects are indirect and occur via modulation of HO-1/ROS signaling, not by direct virus inhibition (Koyaweda et al., 2026).

Workflow Integration & Parameters

For experimental use, dissolve Tin Mesoporphyrin IX (chloride) in DMSO (up to 0.5 mg/mL) or DMF (up to 1 mg/mL) and store at -20°C. Prepare fresh solutions for each experiment to ensure reproducibility. Dosing in animal models typically starts at 1 pmol/kg body weight, with effects on HO activity assayed at intervals up to 24 hours post-administration. In vitro, use nanomolar concentrations in HO activity assays at physiological buffer (pH 7.4, 37°C). Monitor for changes in heme saturation and downstream markers (bilirubin, biliverdin), and validate HO inhibition using enzyme-specific readouts (previous article focuses on experimental insights; here, workflow is contextualized with compound stability).

Conclusion & Outlook

Tin Mesoporphyrin IX (chloride) is a validated, potent heme oxygenase inhibitor, critical for dissecting the roles of HO in metabolism, inflammation, and viral pathogenesis. Its nanomolar competitive inhibition and robust in vivo reproducibility position it as a benchmark research tool. Future work may explore more isoform-selective inhibitors and translational extensions into clinical models, but as of June 2024, its use remains entirely preclinical. APExBIO’s C5606 product provides high-purity material for advanced research into the heme oxygenase signaling pathway.